Exchange Traded Concepts LLC Purchases 15,525 Shares of Precigen, Inc. (NASDAQ:PGEN)

Exchange Traded Concepts LLC boosted its stake in shares of Precigen, Inc. (NASDAQ:PGEN) by 10.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 167,496 shares of the biotechnology company’s stock after purchasing an additional 15,525 shares during the period. Exchange Traded Concepts LLC owned about 0.07% of Precigen worth $159,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in PGEN. Fisher Asset Management LLC bought a new position in Precigen during the fourth quarter valued at approximately $29,000. Fortis Group Advisors LLC bought a new position in Precigen during the first quarter valued at approximately $28,000. Iridian Asset Management LLC CT lifted its position in Precigen by 4.3% during the first quarter. Iridian Asset Management LLC CT now owns 2,091,274 shares of the biotechnology company’s stock valued at $3,032,000 after purchasing an additional 86,340 shares during the period. Vanguard Group Inc. lifted its position in Precigen by 0.3% during the first quarter. Vanguard Group Inc. now owns 6,768,234 shares of the biotechnology company’s stock valued at $9,814,000 after purchasing an additional 19,875 shares during the period. Finally, EntryPoint Capital LLC bought a new position in Precigen during the first quarter valued at approximately $31,000. Institutional investors own 33.51% of the company’s stock.

Precigen Trading Down 2.7 %

PGEN opened at $0.93 on Tuesday. Precigen, Inc. has a 1-year low of $0.82 and a 1-year high of $1.93. The company has a market capitalization of $234.36 million, a PE ratio of -1.72 and a beta of 1.66. The firm’s 50 day simple moving average is $1.00 and its two-hundred day simple moving average is $1.31.

Precigen (NASDAQ:PGEN) last announced its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). The firm had revenue of $0.72 million during the quarter, compared to analysts’ expectations of $1.28 million. Precigen had a negative return on equity of 90.99% and a negative net margin of 3,084.55%. Equities analysts forecast that Precigen, Inc. will post -0.44 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. HC Wainwright lowered their price objective on shares of Precigen from $6.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, August 15th. JMP Securities decreased their price target on shares of Precigen from $14.00 to $7.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 15th. Finally, StockNews.com upgraded shares of Precigen to a “sell” rating in a research report on Thursday, August 1st. Two research analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, Precigen has a consensus rating of “Hold” and a consensus price target of $7.00.

Insider Transactions at Precigen

In other news, SVP Jeffrey Thomas Perez acquired 58,823 shares of Precigen stock in a transaction dated Friday, August 9th. The stock was purchased at an average cost of $0.85 per share, with a total value of $49,999.55. Following the completion of the purchase, the senior vice president now directly owns 743,097 shares in the company, valued at approximately $631,632.45. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 44.90% of the company’s stock.

Precigen Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.